OBJECTIVES: To describe the characteristics of pneumococcal isolates obtained from patients with invasive pneumococcal disease in The Gambia. METHODS: Pneumococcal isolates were obtained from children aged < or =6 years with invasive pneumococcal disease during a Haemophilus influenzae vaccine effectiveness study (1997-2002) and from patients with invasive pneumococcal disease admitted to the MRC hospital, Fajara, for routine care (1996-2003). Isolates were identified, serotyped and tested for antibiotic susceptibility. RESULTS: Five hundred and thirty one pneumococcal isolates were obtained from 518 patients; 55 (10.6%) patients died; 415 isolates (79%) were from blood culture, 84 (16%) from CSF, and 42 (8%) from lung aspirates. Forty serogroups and serotypes were identified; six accounted for 64% and 16 for 86% of all episodes; 33.7% were of serotypes 1 and 5. 23.5% were of a 7-valent vaccine serotype, 57.1% were of a 9-valent vaccine serotype; 56% were of a 7-valent serogroup and 78% were of a 9-valent serogroup. There was a significant increase in the proportion of isolates of non-vaccine serogroup with increasing age (P < 0.0001). Antibiotic resistance had not significantly increased over time; but intermediate non-susceptibility to penicillin had risen and resistance to chloramphenicol had fallen in isolates of vaccine serotype compared with those of non-vaccine serotype. CONCLUSIONS: The majority of invasive pneumococcal disease in The Gambia is caused by pneumococci of relatively few serogroups. A conjugate vaccine would be expected to reduce the pneumococcal disease burden substantially and to have a beneficial effect on pneumococcal antibiotic resistance to penicillins.
OBJECTIVES: To describe the characteristics of pneumococcal isolates obtained from patients with invasive pneumococcal disease in The Gambia. METHODS:Pneumococcal isolates were obtained from children aged < or =6 years with invasive pneumococcal disease during a Haemophilus influenzae vaccine effectiveness study (1997-2002) and from patients with invasive pneumococcal disease admitted to the MRC hospital, Fajara, for routine care (1996-2003). Isolates were identified, serotyped and tested for antibiotic susceptibility. RESULTS: Five hundred and thirty one pneumococcal isolates were obtained from 518 patients; 55 (10.6%) patients died; 415 isolates (79%) were from blood culture, 84 (16%) from CSF, and 42 (8%) from lung aspirates. Forty serogroups and serotypes were identified; six accounted for 64% and 16 for 86% of all episodes; 33.7% were of serotypes 1 and 5. 23.5% were of a 7-valent vaccine serotype, 57.1% were of a 9-valent vaccine serotype; 56% were of a 7-valent serogroup and 78% were of a 9-valent serogroup. There was a significant increase in the proportion of isolates of non-vaccine serogroup with increasing age (P < 0.0001). Antibiotic resistance had not significantly increased over time; but intermediate non-susceptibility to penicillin had risen and resistance to chloramphenicol had fallen in isolates of vaccine serotype compared with those of non-vaccine serotype. CONCLUSIONS: The majority of invasive pneumococcal disease in The Gambia is caused by pneumococci of relatively few serogroups. A conjugate vaccine would be expected to reduce the pneumococcal disease burden substantially and to have a beneficial effect on pneumococcal antibiotic resistance to penicillins.
Authors: Paul Turner; Jason Hinds; Claudia Turner; Auscharee Jankhot; Katherine Gould; Stephen D Bentley; François Nosten; David Goldblatt Journal: J Clin Microbiol Date: 2011-03-16 Impact factor: 5.948
Authors: Merit Melin; Krzysztof Trzciński; Martin Antonio; Seppo Meri; Richard Adegbola; Tarja Kaijalainen; Helena Käyhty; Merja Väkeväinen Journal: Infect Immun Date: 2010-09-20 Impact factor: 3.441
Authors: P Turner; S Melchiorre; M Moschioni; M A Barocchi; C Turner; W Watthanaworawit; N Kaewcharernnet; F Nosten; D Goldblatt Journal: Clin Microbiol Infect Date: 2011-11-16 Impact factor: 8.067
Authors: Martin O C Ota; Anna Roca; Christian Bottomley; Philip C Hill; Uzochukwu Egere; Brian Greenwood; Richard A Adegbola Journal: PLoS One Date: 2012-08-14 Impact factor: 3.240
Authors: Tiffany M Williams; Nicholas J Loman; Chinelo Ebruke; Daniel M Musher; Richard A Adegbola; Mark J Pallen; George M Weinstock; Martin Antonio Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240
Authors: Eric S Donkor; Richard A Stabler; Jason Hinds; Richard A Adegbola; Martin Antonio; Brendan W Wren Journal: BMC Genomics Date: 2012-10-29 Impact factor: 3.969
Authors: Uzochukwu Egere; John Townend; Anna Roca; Abiodun Akinsanya; Abdoulie Bojang; David Nsekpong; Brian Greenwood; Richard A Adegbola; Philip C Hill Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240